Emergent BioSolutions announces $65M agreement to provide Ontario with NARCAN

Emergent BioSolutions (EBS) announced a maximum three-year agreement with a value of approximately $65M to supply the Ontario Ministry of Health with NARCAN Nasal Spray for the Ontario Naloxone Program, or ONP. Since 2018, Emergent has supported the Ontario Ministry of Health to provide access to NARCAN Nasal Spray across the province. NARCAN Nasal Spray is designed to reverse the effects of an opioid poisoning in minutes and is the only 4 mg, intranasal naloxone spray in Canada with a shelf life of four years. From January through March 2025, there were 653 suspect drug-related fatalities in Ontario, which is an average of 7 lives lost per day.1 Data show a promising 30 per cent decrease in overdose deaths from the same period last year.2 Opioid poisonings continue to be a significant threat, and therefore, greater access to life-saving medications, such as NARCAN Nasal Spray, remain critically important. This announcement follows Health Canada’s recent approval of KLOXXADO Nasal Spray 8 mg. Emergent remains committed to bolstering the nation’s efforts to combat the opioid epidemic. Learn more about Emergent’s commitment in Canada via this National Impact Map resource.